New FDA-Approved Treatments for PPD

Author(s):

Carmen Kosicek, MSN, PMHNP-BC,Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss how the recent FDA-approved treatments for postpartum depression (PPD), including zuranolone and brexanolone , offer new options for rapid symptom relief and improve the management of severe PPD cases.

Video Player is loading.

Current Time 0:00

Duration 8:13

Loaded: 0%

Stream Type LIVE

Remaining Time 8:13

EP: 1.Overview of PPD and Current Management Practices

Now Viewing

EP: 2.New FDA-Approved Treatments for PPD

EP: 3.The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP: 4.Diagnostic Tools for PPD

EP: 5.Treatment Choices For PPD and Peripartum Depression

EP: 6.Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP: 7.A Case of PPD in a Mother With a History of Major Depressive Disorder

EP: 8.Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP: 9.Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP: 10.Experts Share Top 7 Recommendations for Treating Postpartum Depression

Related Videos

Overview of Attention Deficit/Hyperactivity Disorder

The Role of Prescription Digital Therapeutics in the Schizophrenia Treatment Landscape

Treatment approach for a mother experiencing PPD already on SSRI

A case of a mother experiencing PPD while on low-dose SSRI

Treatment approach for a mother experiencing PPD at 12 weeks postpartum

A case of a mother experiencing PPD at 12 weeks postpartum

Current and emerging treatments for PPD

Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

Assessing Symptoms, Treatment Decision-Making, and Monitoring

A Case of PPD in a Mother With a History of Major Depressive Disorder